{"preliminary_commentary":{"by_channel":{"x_thread":8},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT07100080\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"IZABRIGHT-Lung01","nct_id":"NCT07100080","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=izabright-lung01-nct07100080. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Arm A","type":"EXPERIMENTAL"},{"description":null,"label":"Arm B","type":"EXPERIMENTAL"},{"description":null,"label":"Arm C","type":"ACTIVE_COMPARATOR"},{"description":null,"label":"Arm D","type":"EXPERIMENTAL"},{"description":null,"label":"Arm E","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2030-11-15","type":"ESTIMATED"},"conditions":["Non-Small Cell Lung Cancer"],"enrollment":{"count":500,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Iza-bren","otherNames":["BMS-986507","BL-B01D1","Izalontamab brengitecan"],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"},{"name":"Pemetrexed","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-09","lead_sponsor":"Bristol-Myers Squibb","official_title":"IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy","overall_status":"RECRUITING","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2028-12-15","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Recommended Phase 3 Dose (RP3D) of BMS-986507","timeFrame":"Approximately 3 months after the first dose"},{"measure":"Progression-Free Survival (PFS) Assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per blinded independent central review (BICR)","timeFrame":"Up to 3 years"}],"references":[],"start_date":{"date":"2025-11-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)","url":"https://clinicaltrials.gov/study/NCT07100080"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/izabright-lung01-nct07100080"}